Company shares last traded at $15.20 which is a tad above $14.45, the stock’s 50 day moving average and marginally over the 200 day moving average of $14.43. The 50 day moving average moved up $0.75 and the 200 day average went up by +5.32%. Trading volume for Meridian Bioscience Inc. was 6,971 on Tuesday. Overall, volume was down 97.83% under the stocks normal daily volume.
Investors are more bullish on shares of the company recently if you take into consideration the fall in short interest. The company recorded a fall in short interest from September 15, 2017 to September 29, 2017 of -1.85%. Short shares decreased from 3,696,115 to 3,627,616 over that timeframe. The short-interest ratio increased to 22.0 and the percentage of shorted shares is 0.09% as of September 29.
Here is a rundown on some insider market activity for Meridian Bioscience Inc. (NASDAQ:VIVO). Chairman John A. Kraeutler disclosed the purchase of 7,000 shares of (VIVO). The shares were purchased at an average price of $13.67. Kraeutler now owns $4,719,294 of the stock according to the SEC filing.
These funds have shifted positions in (VIVO). As of the end of the quarter Creative Planning had bought a total of 11,792 shares growing its position 299.9%. The value of the investment in (VIVO) went from $62,000 to $225,000 a change of $163,000 quarter over quarter. Louisiana State Employees Retirement System trimmed its position by selling 100 shares a decrease of 0.6%. Louisiana State Employees Retirement System claims 17,100 shares worth $245,000. The total value of its holdings decreased 9.6%.
Nisa Investment Advisors, LLC reduced its holdings by shedding 6,500 shares a decrease of 48.8% from 06/30/2017 to 09/30/2017. Nisa Investment Advisors, LLC currently owns 6,820 shares valued at $98,000. The value of the position overall is down by 49.2%. As of quarter end Bank Of Montreal /can/ had disposed of 11,793 shares trimming its holdings by 96.0%. The value of the company’s investment in Meridian Bioscience Inc. decreased from $193,000 to $7,000 a change of 96.4% since the last quarter.
The company currently has a P/E ratio of 30.40 and the market cap of the company is 641.49M. In the last earnings report the EPS was $0.50 and is projected to be $0.68 for the current year with 42,203,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $0.16 with next year’s EPS anticipated to be $0.69.
Meridian Bioscience, Inc., launched on June 25, 1976, is a life science company. The Company is involved in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. The Business’s segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America (the Americas); Europe, Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA (rest of the world (ROW)). Its facility includes research, development, manufacturing, marketing, sales and distribution operations. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia..